F-Phenibut is the fluorinated cousin of phenibut. It activates GABA-B receptors more potently than phenibut and has comparable dependence risk. Not stocked by Kodiac. This monograph is provided for research and educational reference.
Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.
GABA-B agonist / fluoro-phenibut
A 4-fluoro-substituted phenibut analog with higher GABA-B affinity and lower dose requirement; sold as a research chemical with elevated dependence concerns.
Abstract
F-Phenibut (4-amino-3-(4-fluorophenyl)butanoic acid) is a fluorinated analog of phenibut with the addition of a para-fluoro substituent on the phenyl ring. The structural modification increases GABA-B receptor affinity and produces effective doses approximately 5- to 10-fold lower than phenibut. The compound is not approved in any jurisdiction and is sold as a research chemical. Mechanism parallels phenibut (GABA-B agonist) with the affinity increase. Dependence liability is at least as substantial as phenibut and may be greater on a dose-equivalent basis. Pharmacokinetics are not formally characterized in humans; rodent half-life is similar to phenibut. Research-grade vendor doses are typically 50 to 250 mg per administration. F-phenibut should be regarded as a higher-potency phenibut analog with all the dependence concerns of phenibut amplified by potency.
Read the full monograph
The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.